Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: A systematic review and network meta-analysis-Reference-Cited by-同舟云学术

Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: A systematic review and network meta-analysis

Published:2024-04 Issue: Volume:196 Page:104321
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Monteiro Fernando Sabino Marques,Soares Andrey,Mollica Veronica,Leite Caio Abner,Carneiro Andre Paterno Castello Dias,Rizzo Alessandro,Bourlon Maria T.,Sasse Andre Deeke,Santoni Matteo,Gupta Shilpa,Massari Francesco

Publisher

Elsevier BV

Reference49 articles.

1. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review;Abdel-Wahab;Ann. Intern Med.,2018

2. The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer;Atiq;Urol. Oncol.,2023

3. Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a retrospective international study of invasive/advanced cancer of the urothelium (RISC);Bamias;Ann. Oncol.,2018

4. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987;Bellmunt;J. Clin. Oncol.,2012

5. Urothelial carcinoma management in elderly or unfit patients;Bellmunt;EJC Suppl.,2016

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contemporary Molecular Markers for Predicting Systemic Treatment Response in Urothelial Bladder Cancer: A Narrative Review;Cancers;2024-09-01

2. Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project;Targeted Oncology;2024-08-06

3. No difference in oncological outcomes and perioperative complications between patients with ESRD with unilateral and bilateral UTUC receiving radical nephroureterectomy;Scientific Reports;2024-08-01

4. A Head-to-Head Comparison of the First-Line Treatments for Locally Advanced or Metastatic Urothelial Cancer: Is There Still a Role for Chemotherapy?;Cancers;2024-06-29

5. Assessing the predictive value of smoking history for immunotherapy outcomes in bladder cancer patients;Frontiers in Immunology;2024-06-13